false2025-12-31Q20001075880--06-30 0001075880 2025-07-01 2025-12-31 0001075880 2024-07-01 2024-12-31 0001075880 2024-12-31 0001075880 2024-06-30 0001075880 2025-06-30 0001075880 2025-12-31 0001075880 2025-12-02 2025-12-02 0001075880 2025-12-10 0001075880 2025-07-25 0001075880 2025-07-31 2025-07-31 0001075880 2025-07-01 0001075880 2025-01-01 2025-06-30 0001075880 2025-12-02 0001075880 2025-07-31 0001075880 2022-05-01 0001075880 2024-09-04 2024-09-04 0001075880 2025-12-31 2025-12-31 0001075880 ifrs-full:RetainedEarningsMember 2025-07-01 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember 2025-07-01 2025-12-31 0001075880 kzia:OtherContributedEquityMember 2025-07-01 2025-12-31 0001075880 ifrs-full:ReserveOfSharebasedPaymentsMember 2025-07-01 2025-12-31 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2025-07-01 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:IssueDateTwentyfiveJulyTwoThousandTwentyfiveMember kzia:MaximWarrantsNetSettlementMember 2025-07-01 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:IssueDateFiveAugustTwoThousandTwentyfiveMember kzia:AugustPIPEMember 2025-07-01 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:IssueDateTwentyAugustTwoThousandTwentyfiveMember kzia:ATMissueofsharesNumberSixtyFiveMember 2025-07-01 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:IssueDateTwentysevenAugustTwoThousandTwentyfiveMember kzia:ATMIssueOfSharesNunmberSixtySixMember 2025-07-01 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:IssueDateTwelveSeptemberTwoThousandTwentyfiveMember kzia:ATMIssueOfSharesNumberSixtySevenMember 2025-07-01 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:IssueDateThreeOctoberTwoThousandTwentyfiveMember kzia:ATMIssueOfSharesNumberSixtyEightMember 2025-07-01 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:IssueDateThreeDecemberTwoThousandTwentyfiveMember kzia:DecemberPIPENetofTransactionCostsMember 2025-07-01 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:IssueDateTenDecemberTwoThousandTwentyfiveMember kzia:AlumniWarrantsNetSettlementMember 2025-07-01 2025-12-31 0001075880 kzia:IssueDateTwentyfiveJulyTwoThousandTwentyfiveMember kzia:MaximWarrantsNetSettlementMember 2025-07-01 2025-12-31 0001075880 kzia:IssueDateFiveAugustTwoThousandTwentyfiveMember kzia:AugustPIPEMember 2025-07-01 2025-12-31 0001075880 kzia:IssueDateTwentyAugustTwoThousandTwentyfiveMember kzia:ATMissueofsharesNumberSixtyFiveMember 2025-07-01 2025-12-31 0001075880 kzia:IssueDateTwentysevenAugustTwoThousandTwentyfiveMember kzia:ATMIssueOfSharesNunmberSixtySixMember 2025-07-01 2025-12-31 0001075880 kzia:IssueDateTwelveSeptemberTwoThousandTwentyfiveMember kzia:ATMIssueOfSharesNumberSixtySevenMember 2025-07-01 2025-12-31 0001075880 kzia:IssueDateThreeOctoberTwoThousandTwentyfiveMember kzia:ATMIssueOfSharesNumberSixtyEightMember 2025-07-01 2025-12-31 0001075880 kzia:IssueDateThreeDecemberTwoThousandTwentyfiveMember kzia:DecemberPIPENetofTransactionCostsMember 2025-07-01 2025-12-31 0001075880 kzia:IssueDateTenDecemberTwoThousandTwentyfiveMember kzia:AlumniWarrantsNetSettlementMember 2025-07-01 2025-12-31 0001075880 kzia:ShareIssueTransactionCostsMember 2025-07-01 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember kzia:ShareIssueTransactionCostsMember 2025-07-01 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember 2024-07-01 2024-12-31 0001075880 kzia:OtherContributedEquityMember 2024-07-01 2024-12-31 0001075880 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-07-01 2024-12-31 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2024-07-01 2024-12-31 0001075880 ifrs-full:RetainedEarningsMember 2024-07-01 2024-12-31 0001075880 ifrs-full:GrossCarryingAmountMember ifrs-full:LicencesMember 2025-12-31 0001075880 kzia:BasReceivablesMember 2025-12-31 0001075880 kzia:DepositsHeldMember 2025-12-31 0001075880 kzia:InsurancePremiumFundingMember 2025-12-31 0001075880 kzia:CorporateCreditCardDepositMember 2025-12-31 0001075880 ifrs-full:GrossCarryingAmountMember ifrs-full:LicencesMember 2025-06-30 0001075880 kzia:BasReceivablesMember 2025-06-30 0001075880 kzia:DepositsHeldMember 2025-06-30 0001075880 kzia:InsurancePremiumFundingMember 2025-06-30 0001075880 kzia:CorporateCreditCardDepositMember 2025-06-30 0001075880 kzia:UnsecuredConvertiblePromissoryNoteMember 2023-10-23 0001075880 kzia:UnsecuredConvertiblePromissoryNoteMember 2023-12-23 2023-12-23 0001075880 kzia:UnsecuredConvertiblePromissoryNoteMember 2023-12-23 0001075880 kzia:UnsecuredConvertiblePromissoryNoteMember kzia:AmericanDepositarySharesMember 2023-12-23 0001075880 kzia:UnsecuredConvertiblePromissoryNoteMember kzia:AmericanDepositarySharesMember 2024-06-19 0001075880 kzia:UnsecuredConvertiblePromissoryNoteMember ifrs-full:OrdinarySharesMember 2024-06-19 0001075880 kzia:SecuritiesPurchaseAgreementMember 2025-12-02 2025-12-02 0001075880 kzia:PrivatePlacementofEquitySecuritiesMember 2025-12-02 2025-12-02 0001075880 kzia:PrivatePlacementofEquitySecuritiesMember 2025-07-31 0001075880 kzia:SecuritiesPurchaseAgreementMember kzia:PrefundedWarrantsMember 2025-07-31 0001075880 kzia:PrivatePlacementofEquitySecuritiesMember kzia:PrefundedWarrantsMember 2025-07-31 0001075880 kzia:PrivatePlacementofEquitySecuritiesMember 2025-07-31 2025-07-31 0001075880 kzia:PrivatePlacementofEquitySecuritiesMember 2025-12-02 0001075880 kzia:SecuritiesPurchaseAgreementMember kzia:PrefundedWarrantsMember 2025-12-02 0001075880 kzia:PrivatePlacementofEquitySecuritiesMember kzia:PrefundedWarrantsMember 2025-12-02 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2025-06-30 0001075880 ifrs-full:RetainedEarningsMember 2025-06-30 0001075880 ifrs-full:IssuedCapitalMember 2025-06-30 0001075880 kzia:OtherContributedEquityMember 2025-06-30 0001075880 ifrs-full:ReserveOfSharebasedPaymentsMember 2025-06-30 0001075880 ifrs-full:IssuedCapitalMember kzia:IssueDateOneJulyTwoThousandTwentyfiveMember 2025-06-30 0001075880 ifrs-full:IssuedCapitalMember kzia:IssueDateThirtyoneDecemberTwoThousandTwentyfiveMember 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember 2025-12-31 0001075880 kzia:OtherContributedEquityMember 2025-12-31 0001075880 ifrs-full:ReserveOfSharebasedPaymentsMember 2025-12-31 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2025-12-31 0001075880 ifrs-full:RetainedEarningsMember 2025-12-31 0001075880 ifrs-full:IssuedCapitalMember 2024-06-30 0001075880 kzia:OtherContributedEquityMember 2024-06-30 0001075880 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-06-30 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2024-06-30 0001075880 ifrs-full:RetainedEarningsMember 2024-06-30 0001075880 ifrs-full:IssuedCapitalMember 2024-12-31 0001075880 kzia:OtherContributedEquityMember 2024-12-31 0001075880 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-12-31 0001075880 kzia:ForeignCurrencyTranslationReserveMember 2024-12-31 0001075880 ifrs-full:RetainedEarningsMember 2024-12-31 iso4217:AUD xbrli:shares iso4217:USD xbrli:pure iso4217:AUD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form

~~Form~~ 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE

~~PURSUANT TO RULE~~ 13a-16 ~~OR 15d-16~~

15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of

~~For the month of January, 2026~~ March

, 2026

Commission File Number

~~Commission File Number~~ 000-29962

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form

~~Indicate by check mark whether the registrant files or will file annual reports under cover of Form~~ 20-F ~~or Form 40-F.~~

or Form

~~Form 20-F ☒ Form~~ 40-F ☐ .

Form

~~INFORMATION CONTAINED IN THIS FORM 6~~20-~~K REPORT~~ F ☒ Form

On January 27, 2026, Kazia Therapeutics Limited (the “Company”) issued a press release titled “Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late40-~~Stage Metastatic Triple-Negative Breast Cancer”. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.~~ F ☐

INFORMATION CONTAINED IN THIS FORM

The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quotes of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company’s registration statements on Form F6-~~3 (File No. 333-281937).~~ K

REPORT

On March 16, 2026 AEDT, Kazia Therapeutics Limited (the “Company”) reported its unaudited half-year results for the six months ended December 31, 2025, a copy of which is attached to this Form

6-K

as Exhibit 99.1.

The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, into the Company’s

registration

statements on Form

F-3

(File

No. 333-281937).

EXHIBIT LIST

Exhibit		Description
99.1		~~Press~~Half-year ~~Release~~report offor ~~Kazia~~the ~~Therapeutics~~six ~~Limited~~months ~~dated~~ended ~~January~~December 2731, ~~2026~~2025
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant) /s/ John Friend Name: John Friend Title: Chief Executive Officer Date: ~~January~~March 2719, 2026

Filing Compare · KAZIA THERAPEUTICS LTD